ABSTRACT
Objective To investigate the antitumor mechanism of astragaloside combine with cetuximab on the colon cancer cell line RKO of EGFR over expression through cell proliferation and autophagy. Methods The cell proliferation of colon cancer cell line RKO intervened by astragaloside with or without cetuximab was detected by 4- methyl- teerazolium (MTT). The expressive changes for protein of EGFR 、P62 and LC3 in RKO cells was detected by western bolt. Results MTT showed that 100 ug/mL astragaloside combined with 120 ug/mL cetuximab had significantly inhibiting effect on RKO cells of EGFR expression. Western blot showed that astragaloside can affect the expression of P62 and LC3 to suppress the occurrence ofautophagy. Conclusion In the vitro studies showed that astragalosidecan enhance the antitumor cell proliferation of cetuximab through inhibit autophagy in the treatment of colon cancer.
ABSTRACT
Objective To evaluate the curative efficacy and adverse events of in vitro hyperthermia in combination with chemotherapy for treating patients with advanced pancreatic carcinoma .Methods Seventy-five patients with advanced pancreatic carcinoma by pathologic diagnosis admitted in Beijing Friendship Hospital were enrolled and randomly divided into Group Combination ( hyperthermia and chemotherapy ) and Group Chemotherapy at the ratio of 1∶1.All the patients were treated for 4 cycles and the clinical efficacy were evaluated.Results After being treated for 4 cycles, the number of the patients in Group Chemotherapy who had complete response(CR), partial response(PR), stable disease(SD), progressive disease(PD) was 0, 10, 10 and 17, the objective response rate (ORR) was 27.0%, and the disease control rates (DCR) was 54.1%, which in Group Combination was 0, 18, 15 and 5, and 47.4% and 86.8%, respectively.DCR between the two groups was statistically significantly different ( P=0.002 ), but there was no statistical significance on DCR(P=0.069).In Group Combination, the pain relief rate and physical fitness improvement rate was 92.1% and 84.2%, which were significantly higher than 21.6% and 27.0% in Group Chemotherapy, which had statistical significance ( both P<0.05 ).The median survival time and 1-year survival rate in Group Combination was 8.8 months and 31.6%(12/38), which in Group Chemotherapy was 17.86 months and 27.0%(10/37), and there was no statistically significant difference between the two groups .The adverse events in two groups were mild , and no digestive tract reaction with III and IV degree and bone marrow suppression with IV degree were observed .Conclusions DCR and symptom improvement rate in Group Combination were higher than those in Group Chemotherapy , while the adverse events were mild , and patients could tolerate .This combination therapy was worthy of clinical application .